Get the Stockscreener App
6.93
0.03%
-0.03
Annexon Inc stock is traded at $6.93, with a volume of 565.28K.
It is down -0.03% in the last 24 hours and up +36.17% over the past month.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
See More
Previous Close:
$6.96
Open:
$6.98
24h Volume:
565.28K
Relative Volume:
0.21
Market Cap:
$1.03B
Revenue:
-
Net Income/Loss:
$-134.24M
P/E Ratio:
-3.9153
EPS:
-1.77
Net Cash Flow:
$-121.34M
1W Performance:
+14.63%
1M Performance:
+36.17%
6M Performance:
+180.57%
1Y Performance:
+64.11%
1-Day Range:
$6.925
$7.18
1-Week Range:
$5.85
$7.18
52-Week Range:
$1.285
$7.18
Annexon Inc Stock (ANNX) Company Profile
Name
Annexon Inc
Sector
Industry
Phone
(650) 822-5500
Address
1400 SIERRA POINT PARKWAY, BRISBANE
Compare ANNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
6.925 | 1.04B | 0 | -134.24M | -121.34M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.58 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.82 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
830.94 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
363.26 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
341.94 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-23 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-30-23 | Initiated | Wells Fargo | Overweight |
| May-26-23 | Downgrade | BofA Securities | Buy → Neutral |
| May-25-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-16-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | BTIG Research | Buy |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Sep-23-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-26-21 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | BofA Securities | Buy |
| Aug-18-20 | Initiated | Cowen | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
View All
Annexon Inc Stock (ANNX) Latest News
Annexon (NASDAQ:ANNX) Hits New 12-Month HighHere's Why - MarketBeat
Annexon Inc (NASDAQ:ANNX) Advances Complement Biology Platform - Kalkine Media
Annexon (NASDAQ:ANNX) Stock Price Up 9.5%Still a Buy? - MarketBeat
Aug Chart Watch: What are the risks of holding Annexon IncMarket Sentiment Review & Low Risk High Win Rate Picks - baoquankhu1.vn
Does Annexon’s EMA Filing For Tanruprubart Reshape The Bull Case For ANNX? - Yahoo Finance
Annexon (ANNX) Is Up 15.6% After EMA Filing For GBS Antibody Tanruprubart Has The Bull Case Changed? - simplywall.st
Levels Update: Will Annexon Inc benefit from government policyWeekly Investment Summary & Stepwise Trade Signal Guides - baoquankhu1.vn
Assessing Annexon (ANNX) Valuation After EMA Filing For Tanruprubart In Guillain Barre Syndrome - Yahoo Finance
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Annexon (NASDAQ:ANNX) Trading Down 5.9%Here's Why - MarketBeat
Key facts: Annexon to Submit FDA Application for Dry AMD Treatment; Key Milestones Expected in 2026 - TradingView — Track All Markets
Alpha Buying: Managing Biotech Risk With Insider Clues - Benzinga
Annexon Maps “Pivotal” 2026 at JPM Conference: ANX007 Phase 3 GA Readout, ANX005 Filings Ahead - MarketBeat
Annexon, Inc. Updates on Strategic Developments and Product Pipeline - TradingView — Track All Markets
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - Investing News Network
Annexon Biosciences stock rating reiterated by Cantor Fitzgerald - Investing.com Nigeria
Annexon (NASDAQ:ANNX) Hits New 1-Year HighWhat's Next? - MarketBeat
Pharma News: Will Annexon Inc. stock benefit from AI adoptionWeekly Market Report & Weekly Chart Analysis and Guides - Bộ Nội Vụ
Hedge Fund and Insider Trading News: Ray Dalio, Chris Rokos, Steven Cohen, Bill Ackman, Israel Englander, Scott Bessent, Citadel Investment Group, Eisler Capital, Virco Mfg Corp (VIRC), Annexon Inc (ANNX), and More - Insider Monkey
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026 - The Manila Times
Press Telegram - FinancialContent
Annexon, Inc. (NASDAQ:ANNX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Published on: 2026-01-10 21:17:27 - Улправда
Is Annexon Inc. stock safe for conservative investorsJuly 2025 Catalysts & Long-Term Safe Return Strategies - ulpravda.ru
Is Annexon Inc. stock oversold or undervaluedMarket Growth Review & Risk Controlled Swing Trade Alerts - Улправда
Will Annexon Inc. stock beat EPS estimates2025 Pullback Review & Long-Term Growth Portfolio Plans - ulpravda.ru
Will Annexon Inc. stock continue upward momentumJuly 2025 Weekly Recap & Daily Momentum Trading Reports - Улправда
Institutional Investors Have a Lot Riding on Annexon, Inc. (NASDAQ:ANNX) With 68% Ownership - 富途牛牛
Annexon (ANNX) Seeks EMA Approval for Guillain-Barre Syndrome Dr - GuruFocus
Annexon Submits Tanruprubart Marketing Authorization Application To The European Medicines Agency For Guillain-Barré Syndrome - TradingView — Track All Markets
Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome - manilatimes.net
Annexon Submits Tanruprubart Marketing Authorization - GlobeNewswire
Annexon, Inc. to Present at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - Quiver Quantitative
Annexon (NASDAQ:ANNX) Reaches New 1-Year HighShould You Buy? - MarketBeat
Annexon stock rises after director purchases shares - MSN
Insider Buying: William Carson Acquires Additional Shares of Ann - GuruFocus
Insider Buying: Annexon (NASDAQ:ANNX) Director Purchases 4,115 Shares of Stock - MarketBeat
Annexon (NASDAQ:ANNX) Stock Price Down 6.9%Should You Sell? - MarketBeat
What analysts say about Annexon Inc stockMorning Star Patterns & Small Capital Investment Tips - earlytimes.in
Breakout Zone: Will Annexon Inc stock maintain growth story2025 Price Momentum & Growth Oriented Trading Recommendations - moha.gov.vn
Chardan Capital initiates coverage of Annexon (ANNX) with buy recommendation - MSN
Aug Macro: Will WAVE stock continue upward momentumExit Point & Risk Controlled Swing Trade Alerts - moha.gov.vn
Bollinger Bands Expand on Nahar Capital and Financial Services Limited Volatility AheadMerger & Acquisition Updates & Advanced Stock Screening Tools - earlytimes.in
Annexon (NASDAQ:ANNX) Upgraded at Chardan Capital - MarketBeat
Clear Street asserts buy rating on Annexon, Inc. (ANNX) amid progress on pipeline development - MSN
Chardan Capital Initiates Coverage on ANNX with a Buy Rating | A - GuruFocus
Chardan Initiates Annexon at Buy With $16 Price Target - marketscreener.com
Chardan Capital Markets initiates Annexon Biosciences stock with Buy rating By Investing.com - Investing.com South Africa
Chardan Capital Markets initiates Annexon Biosciences stock with Buy rating - Investing.com
Annexon (ANNX) price target increased by 27.19% to 14.79 - MSN
Annexon, Inc.(NasdaqGS: ANNX) added to S&P Biotechnology Select Industry Index - marketscreener.com
Annexon Inc Stock (ANNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.22%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):